HIGHFDA DRUG

Fagron Compounding Services Norepinephrine Bitartrate Injection Recall Affects 5,140 Bags (2026)

Fagron Compounding Services recalled 5,140 bags of norepinephrine Bitartrate injection due to lack of sterility assurance. A blue Break-Off-Part could detach from the administration port. The recall covers nationwide distribution in the U.S. Consumers should stop use and contact providers for guidance.

Official notice
Fagron Compounding ServicesHealth & Personal CareDrugs & MedicationsLot: C274-000050004Exp.: 4/24/2026C274-000050295

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
March 20, 2026
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
March 20, 2026
Hazard Level
HIGH
Brand
Fagron Compounding Services
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT, ELDERLY

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
Fagron Compounding Services
Product type
Iv Solution
Model numbers
Lot: C274-000050004, Exp.: 4/24/2026, C274-000050295, Exp.:5/8/2026, C274-000050773, Exp.: 6/4/2026, C274-000051219, Exp.: 6/21/2026 +4 more
Colors
Blue
Sizes
32 mg per 250 mL 0.9% Sodium Chloride Injection USP
Sold at
Unknown
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    March 20, 2026

  2. Reported by FDA DRUG

    April 15, 2026

  3. RecallRadar source check

    April 22, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Fagron Compounding Services or your healthcare provider for guidance. Notification method: Letter

About This Product

Norepinephrine Bitartrate injections are used as vasopressors in critical care to raise blood pressure in hypotensive patients. They are typically prepared in hospital pharmacies or compounding centers.

Why This Is Dangerous

A blue Break-Off-Part could detach from the administration port, raising sterility concerns and potential contamination risk.

Industry Context

This recall is not part of a broader industry pattern beyond sterility assurance issues in compounded IV solutions.

Real-World Impact

Immediate discontinuation is required for affected bags. Hospitals and patients may experience delays in critical vasopressor therapy while replacements are sourced.

Practical Guidance

How to identify if yours is affected

  1. Confirm NDC 71266-5027-02 and product description.

Where to find product info

Recall details are on FDA enforcement page and packaging labels.

What timeline to expect

Refunds/replacements typically managed through hospital purchasing channels; no public timeline specified.

If the manufacturer is unresponsive

  • Engage hospital risk management or compliance.
  • File a formal inquiry with the manufacturer and FDA if no response within a reasonable period.

How to prevent similar issues

  • Implement strict lot-based inventory control.
  • Institute supplier sterility confirmation before use.
  • Audit compounded IV solutions for break-off components.

Documentation advice

Document lot numbers, expiration dates, and correspondences with the manufacturer and FDA.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Product: Norepinephrine Bitartrate, 32 mg per 250 mL 0.9% Sodium Chloride Injection USP. Company: Fagron Compounding Services. Address: 8710 34th St. N. Wichita, KS 67226. NDC: 71266-5027-02. Lot numbers and expirations include: C274-000050004 Exp. 4/24/2026; C274-000050295 Exp. 5/8/2026; C274-000050773 Exp. 6/4/2026; C274-000051219 Exp. 6/21/2026; C274-000051318 Exp. 6/27/2026; C274-000051602 Exp. 7/12/2026. Quantity: 5140 bags. Distribution: Nationwide in the USA. Recall date: 2026-03-20.

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • Lot numbers with expirations listed (4/24/2026 to 7/12/2026)
  • Nationwide distribution in the U.S.
  • Hazard: lack of sterility assurance; blue Break-Off-Part could detach

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANTELDERLYPETS
Injury Types
ELECTRICALPOISONINGLACERATIONOTHER

Product Details

Model Numbers
Lot: C274-000050004
Exp.: 4/24/2026
C274-000050295
Exp.:5/8/2026
C274-000050773
+7 more
Affected States
ALL
Report Date
April 15, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls